Cesium131 Prostate Brachytherapy: An early experience

Brachytherapy

April 16, 2007

Dr. Moran from Chicago reports on 104 patients implanted with Cesium-131 for localized prostate cancer. Serum PSAs in these patients dropped precipitously as expected given the typical response of PSA to successful brachytherapy. Patient-reported urinary symptoms had returned to pre-treatment levels in the great majority of patients by six months, which may represent an advantage over other brachytherapy isotopes.

IPSS trends for Cs-131 permanent prostate brachytherapy

Authors: Andrew Jones, Ph.D., Jared Treas, M.S., John Danella, M.D., Omar Yumen, M.D.

The determination of radiobiologically optimized half-lives for radionuclides used in permanent brachytherapy implants.

Authors: Armpilia CI, Dale RG, Coles IP, Jones B, Antipas V.